呼吸器疾患ワクチン市場：感染症別、タイプ別、年齢層別-2025-2030年の世界予測

呼吸器疾患ワクチン市場は、2023年に234億2,000万米ドルと評価され、2024年には247億8,000万米ドルに達すると予測され、CAGR 5.87%で成長し、2030年には349億3,000万米ドルに達すると予測されています。

呼吸器疾患ワクチン市場の範囲と定義には、インフルエンザ、COVID-19、呼吸器合胞体ウイルス（RSV）など、呼吸器系に影響を及ぼす疾患の予防を目的としたワクチンの開発、生産、流通が含まれます。これらのワクチンの必要性は、重大な罹患率や死亡率を引き起こし、公衆衛生システムや経済に影響を与える呼吸器系疾患の世界の持続的負担によって強調されています。呼吸器系ワクチンの用途は多岐にわたり、小児から成人まで、季節的なワクチン接種キャンペーンと集団発生への対応イニシアティブの両方に及んでいます。最終用途の範囲は、主に病院や診療所などのヘルスケア機関を対象としており、政府の予防接種プログラムや個人消費者にも及んでいます。

市場成長の原動力は、予防ヘルスケアに対する意識の高まり、ワクチン技術の進歩、ワクチン接種プログラムに対する政府の支援といった要因です。現在進行中のCOVID-19パンデミックは、この分野への投資と研究をさらに加速させ、mRNAワクチンや経鼻デリバリーシステムなどのイノベーションに潜在的な機会を提供しています。企業は、効果的な市場浸透戦略のために、共同研究パートナーシップやデータ分析の活用に注力すべきです。しかし、市場開拓は、高い開発コスト、規制上のハードル、住民のワクチン離れのような課題に直面しています。また、サプライチェーンの完全性を維持し、保管・流通ロジスティクスに対処することも大きな制約となります。

こうした機会を活用するため、企業は、より広範な保護を提供する万能ワクチンの開発や、ワクチンの有効性と流通の最適化における予測モデリングのための人工知能の統合といった分野に投資することができます。コールドチェーン・ロジスティクスの革新や、ワクチン生産のための植物ベースおよび宿主ベクター・システムの探求は、今後の成長が期待される研究分野です。市場はダイナミックで、バイオテクノロジー、医療科学、データ分析にまたがる学際的な性質を持っており、成功のためには調和の取れたアプローチが必要です。需要の高まり、技術の進歩、規制遵守に効果的に対処する企業は、急速に進化する呼吸器疾患ワクチン市場で成功するための戦略的なポジションを得ることができると思われます。

市場力学：急速に進化する呼吸器疾患ワクチン市場の主要市場インサイトを公開

呼吸器疾患ワクチン市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 呼吸器疾患の有病率の増加
  • パイプラインにある臨床試験とワクチン開発
  • 呼吸器の健康を支援する政府の取り組み
• 市場抑制要因
  • 不十分な医療インフラと限られた認識
• 市場機会
  • 主要企業による研究開発費の増加
  • 再販提携によるワクチン入手の増加
• 市場の課題
  • 呼吸器疾患ワクチン接種に対する消費者の信頼と信用

ポーターの5つの力：呼吸器疾患ワクチン市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することで、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：呼吸器疾患ワクチン市場における外部からの影響の把握

外部マクロ環境要因は、呼吸器疾患ワクチン市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析呼吸器疾患ワクチン市場における競合情勢の把握

呼吸器疾患ワクチン市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス呼吸器疾患ワクチン市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、呼吸器疾患ワクチン市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨呼吸器疾患ワクチン市場における成功への道筋を描く

呼吸器疾患ワクチン市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 呼吸器疾患の罹患率の増加
    • パイプライン内の臨床試験とワクチン開発
    • 呼吸器の健康をサポートする政府の取り組み
  • 抑制要因
    • 不十分な配送インフラと限られた認知度の欠如
  • 機会
    • 主要企業による研究開発費の増加
    • 再販協力を通じてワクチンの入手可能性を高める
  • 課題
    • 呼吸器疾患ワクチンに対する消費者の信頼と自信
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 呼吸器疾患ワクチン市場感染別

• インフルエンザウイルス
• 百日咳
• 肺炎球菌
• 結核

第7章 呼吸器疾患ワクチン市場：タイプ別

• 細菌ワクチン
• 混合ワクチン
• ウイルスワクチン

第8章 呼吸器疾患ワクチン市場：年齢層別

• 青少年の予防接種
• 成人の予防接種
• 乳児の予防接種

第9章 南北アメリカの呼吸器疾患ワクチン市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の呼吸器疾患ワクチン市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの呼吸器疾患ワクチン市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Astrazeneca PLC
• Bavarian Nordic A/S
• Bharat Biotech International Ltd.
• CanSino Biologics Inc.
• Emergent BioSolutions, Inc.
• GlaxoSmithKline PLC
• Johnson & Johnson Services, Inc.
• Merck & Co., Inc.
• Moderna, Inc.
• Pfizer Inc.
• Sanofi S.A.
• Seqirus USA Inc.
• Serum Institute of India Pvt. Ltd.
• Sinovac Biotech Ltd.
• Vaxine Pty Ltd.

LIST OF FIGURES

• FIGURE 1. RESPIRATORY DISEASE VACCINE MARKET RESEARCH PROCESS
• FIGURE 2. RESPIRATORY DISEASE VACCINE MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. RESPIRATORY DISEASE VACCINE MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. RESPIRATORY DISEASE VACCINE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. RESPIRATORY DISEASE VACCINE MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. RESPIRATORY DISEASE VACCINE MARKET DYNAMICS
• TABLE 7. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFLUENZA VIRUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PERTUSSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY STREPTOCOCCUS PNEUMONIAE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TUBERCULOSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY BACTERIAL VACCINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COMBINATION VACCINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VIRAL VACCINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADOLESCENT VACCINATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADULT VACCINATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFANT VACCINATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 26. ARGENTINA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 27. BRAZIL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
• TABLE 28. BRAZIL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 29. BRAZIL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 30. CANADA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
• TABLE 31. CANADA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 32. CANADA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 33. MEXICO RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
• TABLE 34. MEXICO RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 35. MEXICO RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 39. UNITED STATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 43. ASIA-PACIFIC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 44. AUSTRALIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
• TABLE 45. AUSTRALIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 46. AUSTRALIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 47. CHINA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
• TABLE 48. CHINA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 49. CHINA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 50. INDIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
• TABLE 51. INDIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 52. INDIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 53. INDONESIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
• TABLE 54. INDONESIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 55. INDONESIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 56. JAPAN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
• TABLE 57. JAPAN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 58. JAPAN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 59. MALAYSIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
• TABLE 60. MALAYSIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 61. MALAYSIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 62. PHILIPPINES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
• TABLE 63. PHILIPPINES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 64. PHILIPPINES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 65. SINGAPORE RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
• TABLE 66. SINGAPORE RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 67. SINGAPORE RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 68. SOUTH KOREA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
• TABLE 69. SOUTH KOREA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 70. SOUTH KOREA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 71. TAIWAN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
• TABLE 72. TAIWAN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 73. TAIWAN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 74. THAILAND RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
• TABLE 75. THAILAND RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 76. THAILAND RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 77. VIETNAM RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
• TABLE 78. VIETNAM RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 79. VIETNAM RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 83. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 84. DENMARK RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
• TABLE 85. DENMARK RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 86. DENMARK RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 87. EGYPT RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
• TABLE 88. EGYPT RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 89. EGYPT RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 90. FINLAND RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
• TABLE 91. FINLAND RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 92. FINLAND RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 93. FRANCE RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
• TABLE 94. FRANCE RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 95. FRANCE RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 96. GERMANY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
• TABLE 97. GERMANY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 98. GERMANY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 99. ISRAEL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
• TABLE 100. ISRAEL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 101. ISRAEL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 102. ITALY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
• TABLE 103. ITALY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 104. ITALY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 105. NETHERLANDS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
• TABLE 106. NETHERLANDS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 107. NETHERLANDS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 108. NIGERIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
• TABLE 109. NIGERIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 110. NIGERIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 111. NORWAY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
• TABLE 112. NORWAY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 113. NORWAY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 114. POLAND RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
• TABLE 115. POLAND RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 116. POLAND RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 117. QATAR RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
• TABLE 118. QATAR RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 119. QATAR RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 120. RUSSIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
• TABLE 121. RUSSIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 122. RUSSIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 123. SAUDI ARABIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
• TABLE 124. SAUDI ARABIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 125. SAUDI ARABIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 128. SOUTH AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 129. SPAIN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
• TABLE 130. SPAIN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 131. SPAIN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 132. SWEDEN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
• TABLE 133. SWEDEN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 134. SWEDEN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 135. SWITZERLAND RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
• TABLE 136. SWITZERLAND RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 137. SWITZERLAND RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 138. TURKEY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
• TABLE 139. TURKEY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 140. TURKEY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 141. UNITED ARAB EMIRATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
• TABLE 142. UNITED ARAB EMIRATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 143. UNITED ARAB EMIRATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 144. UNITED KINGDOM RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
• TABLE 145. UNITED KINGDOM RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 146. UNITED KINGDOM RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 147. RESPIRATORY DISEASE VACCINE MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 148. RESPIRATORY DISEASE VACCINE MARKET, FPNV POSITIONING MATRIX, 2023

The Respiratory Disease Vaccine Market was valued at USD 23.42 billion in 2023, expected to reach USD 24.78 billion in 2024, and is projected to grow at a CAGR of 5.87%, to USD 34.93 billion by 2030.

The scope and definition of the respiratory disease vaccine market encompass the development, production, and distribution of vaccines aimed at preventing diseases affecting the respiratory system, such as influenza, COVID-19, and respiratory syncytial virus (RSV). The necessity of these vaccines is underscored by the persistent global burden of respiratory illnesses, which cause significant morbidity and mortality, impacting public health systems and economies. The application of respiratory vaccines is robust, involving both pediatric and adult populations, and spans both seasonal vaccination campaigns and outbreak response initiatives. End-use scope primarily covers healthcare institutions, including hospitals and clinics, and extends to government vaccination programs and individual consumers.

Market growth is driven by factors such as increasing awareness about preventive healthcare, advances in vaccine technologies, and governmental support for vaccination programs. The ongoing COVID-19 pandemic has further accelerated investments and research in this sector, providing potential opportunities for innovations like mRNA vaccines and intranasal delivery systems. Companies should focus on collaborative research partnerships and leveraging data analytics for effective market penetration strategies. However, market growth faces challenges like high development costs, regulatory hurdles, and vaccine hesitancy among populations. Maintaining supply chain integrity and addressing storage and distribution logistics also pose significant limitations.

To capitalize on these opportunities, businesses can invest in areas like the development of universal vaccines that offer broader protection and the integration of artificial intelligence for predictive modeling in vaccine efficacy and distribution optimization. Innovation in cold chain logistics and exploring plant-based and host-vector systems for vaccine production are promising research areas for future growth. The market is dynamic, with a multidisciplinary nature that spans biotechnology, medical science, and data analytics, requiring a harmonized approach for success. Companies that effectively address the rising demand, technological advancements, and regulatory compliance will be strategically positioned to thrive in the rapidly evolving respiratory disease vaccine market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Respiratory Disease Vaccine Market

The Respiratory Disease Vaccine Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of respiratory disorders
  • Clinical trials and vaccines developments in pipeline
  • Government initiatives supporting respiratory health
• Market Restraints
  • Lack of inadequate delivery infrastructure & limited awareness
• Market Opportunities
  • Increasing R&D expenditure by leading companies
  • Increase vaccine availability through reselling collaborations
• Market Challenges
  • Consumer trust & confidence in respiratory disease vaccination

Porter's Five Forces: A Strategic Tool for Navigating the Respiratory Disease Vaccine Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Respiratory Disease Vaccine Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Respiratory Disease Vaccine Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Respiratory Disease Vaccine Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Respiratory Disease Vaccine Market

A detailed market share analysis in the Respiratory Disease Vaccine Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Respiratory Disease Vaccine Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Respiratory Disease Vaccine Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Respiratory Disease Vaccine Market

A strategic analysis of the Respiratory Disease Vaccine Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Respiratory Disease Vaccine Market, highlighting leading vendors and their innovative profiles. These include Astrazeneca PLC, Bavarian Nordic A/S, Bharat Biotech International Ltd., CanSino Biologics Inc., Emergent BioSolutions, Inc., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Merck & Co., Inc., Moderna, Inc., Pfizer Inc., Sanofi S.A., Seqirus USA Inc., Serum Institute of India Pvt. Ltd., Sinovac Biotech Ltd., and Vaxine Pty Ltd..

Market Segmentation & Coverage

This research report categorizes the Respiratory Disease Vaccine Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Infection, market is studied across Influenza Virus, Pertussis, Streptococcus Pneumoniae, and Tuberculosis.
• Based on Type, market is studied across Bacterial Vaccine, Combination Vaccine, and Viral Vaccine.
• Based on Age Group, market is studied across Adolescent Vaccination, Adult Vaccination, and Infant Vaccination.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of respiratory disorders
    • 5.1.1.2. Clinical trials and vaccines developments in pipeline
    • 5.1.1.3. Government initiatives supporting respiratory health
  • 5.1.2. Restraints
    • 5.1.2.1. Lack of inadequate delivery infrastructure & limited awareness
  • 5.1.3. Opportunities
    • 5.1.3.1. Increasing R&D expenditure by leading companies
    • 5.1.3.2. Increase vaccine availability through reselling collaborations
  • 5.1.4. Challenges
    • 5.1.4.1. Consumer trust & confidence in respiratory disease vaccination
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Respiratory Disease Vaccine Market, by Infection

• 6.1. Introduction
• 6.2. Influenza Virus
• 6.3. Pertussis
• 6.4. Streptococcus Pneumoniae
• 6.5. Tuberculosis

7. Respiratory Disease Vaccine Market, by Type

• 7.1. Introduction
• 7.2. Bacterial Vaccine
• 7.3. Combination Vaccine
• 7.4. Viral Vaccine

8. Respiratory Disease Vaccine Market, by Age Group

• 8.1. Introduction
• 8.2. Adolescent Vaccination
• 8.3. Adult Vaccination
• 8.4. Infant Vaccination

9. Americas Respiratory Disease Vaccine Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Respiratory Disease Vaccine Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Respiratory Disease Vaccine Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Astrazeneca PLC
• 2. Bavarian Nordic A/S
• 3. Bharat Biotech International Ltd.
• 4. CanSino Biologics Inc.
• 5. Emergent BioSolutions, Inc.
• 6. GlaxoSmithKline PLC
• 7. Johnson & Johnson Services, Inc.
• 8. Merck & Co., Inc.
• 9. Moderna, Inc.
• 10. Pfizer Inc.
• 11. Sanofi S.A.
• 12. Seqirus USA Inc.
• 13. Serum Institute of India Pvt. Ltd.
• 14. Sinovac Biotech Ltd.
• 15. Vaxine Pty Ltd.